The company doesn't have a financial crisis at hand and pays a handsome dividend. The question is, Does the company become more efficient selling and manufacturing its products?

I don't see any pressure on them to settle in the near term.

I've got to look sharp. You're talking to the sheriff of this county.

I've never seen anything like that. And hopefully, nobody else will have to.

There's not a company that's not swept up in this wave of cost analysis,

We believe Pfizer is more likely to either sell this consumer health business or perhaps create some type of partnership with another consumer health business where synergies could exist.

I think that what we continue to learn is that the hurdle rate of the FDA has gotten higher,

We're probably looking at short term, that's from now until January. But there are also emergency loans which start from one month and can be extended to three so they are a possibility as well.

Pfizer and American Home Products will be manic and poised to lead the group, Bristol-Myers Squibb and Merck appear to be stick in the middle and Eli Lilly and Schering-Plough will be down in the dumps,

With Viagra you've got an onset of action of an hour and it lasts for four hours, and here's a new drug that has an onset of 16 minutes and lasts all day, ... Which might appeal for someone who wants to have more flexibility with their sexual experience.